Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, open label comparative study of azithromycin extended release (Zmax) versus amoxicillin/clavulanate potassium [clavulanic acid] in subjects with acute bacterial sinusitis (ABS) in a physician practice environment

Trial Profile

A multicenter, randomized, open label comparative study of azithromycin extended release (Zmax) versus amoxicillin/clavulanate potassium [clavulanic acid] in subjects with acute bacterial sinusitis (ABS) in a physician practice environment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amoxicillin/clavulanic acid (Primary) ; Azithromycin (Primary)
  • Indications Acute sinusitis; Bacterial infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Mar 2010 Patient numbers amended from 749 to 762 as reported by ClinicalTrials.gov.
    • 01 Feb 2010 Results published in the American Journal of Otolaryngology - Head and Neck Medicine and Surgery.
    • 20 Sep 2007 Status change from in progress to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top